Oramed Pharmaceuticals
ORMP
28 hedge funds and large institutions have $5.7M invested in Oramed Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
3,600% more call options, than puts
Call options by funds: $111K | Put options by funds: $3K
0.91% more ownership
Funds ownership: 10.03% → 10.94% (+0.91%)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
33% less capital invested
Capital invested by funds: $8.45M → $5.7M (-$2.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$546K |
| 2 |
SFFS
Stonehage Fleming Financial Services
St. Helier,
Jersey
|
+$318K |
| 3 |
BlackRock
New York
|
+$166K |
| 4 |
Renaissance Technologies
New York
|
+$73.2K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$66.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$336K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$114K |
| 3 |
Squarepoint
New York
|
-$71K |
| 4 |
CAM
Close Asset Management
London,
United Kingdom
|
-$7.45K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$6.21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Nordea Investment Management
Stockholm,
Sweden
| $2K | +$2.07K | +500 | New |
|
|
FHA
27
Flagship Harbor Advisors
Boston,
Massachusetts
| $2K | +$2.9K | +700 | New |
|
|
GT
28
Glenmede Trust
Philadelphia,
Pennsylvania
| $60 | – | – | – |
|
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$114K | -23,345 | Closed |
|
|
30
Squarepoint
New York
| – | -$71K | -14,500 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$4K | -861 | Closed |
|
|
SPIA
32
Steward Partners Investment Advisory
New York
| – | -$1K | -300 | Closed |
|
ORMP Hedge Fund Activity: Q4 2018 in Review
28 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2018, worth a combined $5.7M — down 33% from $8.45M a quarter earlier.
Fund positioning in ORMP was balanced in Q4 2018: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Sabby Management, adding an estimated $546K. The largest seller was Armistice Capital, cutting an estimated $336K.
- 28 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $5.7M of Oramed Pharmaceuticals stock for Q4 2018, down 33% quarter-over-quarter.
- 4 funds opened new Oramed Pharmaceuticals positions in Q4 2018 and 4 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2018 was Sabby Management, an estimated $546K added.
- The largest Oramed Pharmaceuticals seller in Q4 2018 was Armistice Capital, an estimated $336K sold.
Based on aggregated 13F filings for Q4 2018.